Terminated PHASE3 INTERVENTIONAL 2-arm NCT01387932

HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer (HiQuality)

Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma

Sponsor: Merit Medical Systems, Inc.

Conditions Hepatocellular Carcinoma

Interventions HepaSphere/QuadraSphere Microspheres PVA, lipiodol, doxorubicin

Updated 15 times since 2017 Last updated: Nov 2, 2021 Started: Jun 30, 2011 Primary completion: Feb 28, 2021 Completion: Feb 28, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The clinical study was terminated due to the inability to meet target enrollment.

Other terminated trials from Merit Medical Systems, Inc.

More terminations from Merit Medical Systems, Inc.

Other Hepatocellular Carcinoma trials with similar outcome

Browse all Hepatocellular Carcinoma trials

This PHASE3 trial investigates Hepatocellular Carcinoma and is currently terminated or withdrawn. Merit Medical Systems, Inc. leads this study, which shows 15 recorded versions since 2011 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

15 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jun 2021 — Dec 2021 [monthly]

Terminated PHASE3

Status: Active Not Recruiting → Terminated

▶ Show 10 earlier versions

Jan 2021 — Jun 2021 [monthly]

Active Not Recruiting PHASE3
Oct 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE3
Mar 2020 — Oct 2020 [monthly]

Active Not Recruiting PHASE3
Feb 2020 — Mar 2020 [monthly]

Active Not Recruiting PHASE3
Sep 2019 — Feb 2020 [monthly]

Active Not Recruiting PHASE3
Jun 2018 — Sep 2019 [monthly]

Active Not Recruiting PHASE3
May 2018 — Jun 2018 [monthly]

Active Not Recruiting PHASE3
Aug 2017 — May 2018 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Feb 2017 — Aug 2017 [monthly]

Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE3

First recorded

Jun 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merit Medical Systems, Inc.

Data source: Merit Medical Systems, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Athens, Greece , Birmingham, United States , Bordeaux, France , Boston, United States , Charleston, United States , Chicago, United States , Cuneo, Italy , Leuven, Belgium , Little Rock, United States and 11 more locations